Since erythropoietin’s use was associated to a possible risk of thromboembolism [18], we performed regular clinical and laboratory monitoring of LT candidates on erythropoietin treatment also in consideration that the waiting time for a suitable deceased donor is unpredictable. Here, EPO is linked to Thromboembolism.